Specifically, Ulixertinib is an ATP-competitive inhibitors of ERK1/2 that selectively and reversibly inhibits ERK1/2, leading to cell cycle arrest and apoptosis in tumor cells [122]. This evidence concerns the gene MAPK3 and neoplasm.